
NeoNeuro Receives Investment from ADDF
NeoNeuro Receives Investment from ADDF NeoNeuro announced today that the Alzheimer’s Drug Discovery Foundation (ADDF) invested in the company through

NeoNeuro Receives Investment from ADDF NeoNeuro announced today that the Alzheimer’s Drug Discovery Foundation (ADDF) invested in the company through

Blood Based Diagnostics of Alzheimer’s Disease. Early detection of Alzheimer’s disease (AD) relies on identifying reliable biomarkers in blood. In

Aptamers as Biomarkers for Neurological Disorders. Proof of Concept in Transgenic Mice Blood-based diagnostics provide a minimally invasive way to

NeoNeuro Partners with the INSIGHT Cohort NeoNeuro SAS has entered into a collaboration under the leadership of Professor Harald Hampel

NeoNeuro Collaborates with the AIBL Study NeoNeuro SAS is pleased to announce a collaboration with the Australian Imaging, Biomarker &

NeoNeuro Awarded a New BPI France Grant NeoNeuro recently received a new grant from BPI France to advance research on

NeoNeuro Receives BPI France Grant NeoNeuro has received support from BPI France under the PIA-1 program to advance the use